The persistence of lung cancer stem cells (LCSCs) has been proposed to be the main factor responsible for the recurrence of lung cancer as they are highly resistant to conventional chemotherapy. However, the underlying mechanisms are still unclear.
Introduction
Lung cancer is estimated to account for the highest number of deaths among all the various types of cancer, and about 224 390 new cases are expected in the United States in 2016 (American Cancer Society, 2016) . Lung cancer is known to have a high recurrence rate, since lung cancer cells cannot be completely eliminated by conventional chemotherapeutics due to the development of drug resistance (Chen et al., 2013) . A cancer stem cell (CSC) model has been proposed to explain the high rate of recurrence of lung cancer (Bonnet and Dick, 1997) . CSCs are known to exist as important subpopulations in tumours and contribute to various functional characteristics such as tumourigenesis and heterogeneity (Singh et al., 2004) . Recently, the lung CSC (LCSC) model has been further investigated and a rare population of tumour-initiating cells was identified and shown to contribute to the self-renewal and replacement of various heterogeneous cancer cell populations within a tumour in a hierarchical manner (Kubo et al., 2013) . LCSCs are the potential cause of relapse because of their high expression of stemness-related genes, their invasiveness, drug resistance and ability to proliferate, and tumorigenicity (Bonnet and Dick, 1997; Al-Hajj et al., 2003) .
Chemotherapy is still one of the standard treatment regimens for lung cancers and involves the use of different chemotherapeutic agents. Among them, cisplatin [cisdiamminedichloroplatinum(II)] is a first-line chemotherapeutic DNA-damaging drug used to treat lung cancer, which is commonly administered together with other non-platinum-based chemotherapeutic drugs to increase the survival rates of lung cancer patients (van Moorsel et al., 1999) . The mechanism of action of cisplatin has been extensively investigated (Wang and Lippard, 2005) . It is now widely agreed that DNA is the major target of cisplatin. Cisplatin forms adducts of mainly intrastrand platinum (Pt)-DNA cross-links, with a minor proportion of interstrand cross-links (ICLs) (Fichtinger-Schepman et al., 1985) . Pt-DNA cross-links induce apoptosis by inhibiting DNA replication and transcription. Complex mechanisms are involved in cisplatin resistance. For example, reduced cellular uptake and elevated efflux are the potential causes of cisplatin resistance (Wang and Lippard, 2005) . The resistance can also be attributed to activation of different DNA repair pathways including nucleotide excision repair (NER), based excision repair (BER), mismatch repair (MMR) and single-strand break repair (SSBR), which are responsible for the removal of Pt-DNA cross-links (Graf et al., 2011; Enoiu et al., 2012) . Cisplatin resistance has been correlated well with an increased ability to induce DNA repairs (Bartucci et al., 2012) , which makes complete elimination of a tumour more difficult.
Although the mode of action and biological properties of cisplatin have been widely described, our knowledge of cisplatin's action in LCSCs is still vague. In addition, how these LCSCs generate drug resistance is still debatable. Cisplatin resistance has been correlated with the stem-like characteristics of some lung cancer cells (Barr et al., 2013) . Recently, cisplatin-resistant lung cancer cells were generated and these cells were shown to exhibit stemness characterized by the expression of CSC markers, CD133 and CD44, and by an elevated aldehyde dehydrogenase (ALDH) activity (Barr et al., 2013) . Another study also demonstrated that a lung tumour cell subpopulation with high ALDH and CD44 coexpression displayed increased cisplatin resistance and other tumourigenic properties (Liu et al., 2013a) . Cisplatin enhances the CD133 + population that exhibits CSC-like characteristics in lung cancer cells (Bertolini et al., 2009; Liu et al., 2013b) . These results indicate that stemness and cisplatin resistance are highly correlated in lung cancer. While some studies claim that the reduced accumulation of cisplatin is the major cause of platinum resistance (Ishida et al., 2002; Safaei and Howell, 2005; Hall et al., 2008) , Eljack and colleagues showed that passive diffusion rather than reduced cellular uptake of cisplatin is an important mechanism for drug resistance (Eljack et al., 2014) . However, the details of how these stem-like cancer cells mediate cisplatin resistance are not fully understood.
In the present study, we used a human LCSC line as the model system to study the mechanism of cisplatin resistance and its correlation with cell stemness. We first measured the viability of LCSCs and differentiated LCSCs (dLCSCs) after cisplatin treatment. We next scrutinized the detailed mechanism of cisplatin resistance in LCSCs. The accumulation of platinum in cells as well as the level of platinum on genomic 
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Methods
Cell culture and characterization of human lung cancer cell lines
LCSCs were purchased from Celprogen (USA) and cultured in human parent LCSC media with serum-free supplement. They are known to express a list of biomarkers, such as CD15 and CD20 (Detail information: http://www.celprogen. com/details.php?pid=6423). This cell line was briefly characterized as described in a previous report (Zou et al., 2015) . Third generation LCSCs (P3) were used in this study, and dLCSCs originated from LCSCs after 12 passages (P13) in the culture with an obvious change in cell morphology. dLCSCs were cultured in DMEM/F-12 medium with 10% FBS and 1% of the antibiotics, penicillin (100 U·mL À1 ) and streptomycin (100 g·mL À1 ). The changes in expression of stemness-related genes in both LCSCs and dLCSCs were characterized by qRT-PCR. All cells were grown at 37°C in a 5% CO 2 incubator.
Immunostaining and FACS analysis
LCSCs and dLCSCs were cultured on 55 cm 2 culture dishes.
After reaching 90% confluency, cells were detached, washed with PBS and fixed in 4% (v.v -1 ) paraformaldehyde for 15 min. Cells were then permeabilized in blocking solution containing 0.5% Triton X100, 1% FBS in PBS. Fluoresceinconjugated Oct-3/4 antibody was subsequently added to stain nuclear Oct4 in blocking solution for 1 h. After being washed in PBS containing 0.5% Triton X100, cells were resuspended in PBS and loaded onto a flow cytometer (CantoII, BD Biosciences) for FITC signal detection using a 488 nm laser. Unstained cells were used as negative controls; events that had fluorescent intensities higher than any of the negative controls were considered to be positive; a line segment was drawn to indicate this region on the flow cytometric diagram.
Immunofluorescence microscopy
Ten thousand LCSCs or dLCSCs were seeded onto slides coated with poly-L-lysine (Sigma), respectively, and they were allowed to attach onto the surface by overnight incubation at 37°C. Before being stained, the cells were washed with PBS and fixed in 4% (v.v -1 ) paraformaldehyde and permeabilized with Triton X100, similar to the above method for immunostaining. After the staining with FITC conjugated Oct4 antibody, Hoechst 33 342 (molecular probes) was used to stain the nucleus. Slides were mounted using 22 mm coverslips (VWR), and cells were imaged using a fluorescence microscope (Leica DMI3000B) with excitation filters of 360/40BP (Hoechst 33 342) and 470/40BP (FITC).
Quantitative real-time PCR of stemness-related genes, drug transporters and DNA repair-related genes Total RNA of LCSCs and dLCSCs was extracted using TRIzol reagent, and 3 μg of total RNA was reverse transcribed into cDNA by SuperScript ™ III reverse transcriptase.
Quantitative real-time PCR was performed by adding SYBR Green Master Mix to cDNA using specific primers for stemness-or transporter-related genes. All primer sequences were listed in the supplementary section. Gene expression levels were analysed by ABI 7500 Fast Real-Time PCR System (Applied Biosciences) using the following conditions: 1 cycle at 95°C for 10 min, 40 cycles at 95°C for 15 s and 60°C for 1 min, and fold changes of genes were calculated using the formula 2 -(ddCt) .
To investigate the expression of DNA repair pathwayrelated genes in the two cell lines, the cells were seeded in six-well plates and treated with 50 μM of cisplatin or cisplatin-free medium for 12 h. This treatment regime was based on the results from the cell viability, comet and transcription assays. The cisplatin-treated cells were collected after 12 h and compared with those without treatment for changes in gene expression. Real-time PCR analysis was performed, as mentioned above. Primer sequences are also included in Table S1 .
Tumour sphere formation assay
LCSCs and dLCSCs were seeded at a density of 10 000 cells per well in six-well non-adherent plates in DMEM/F12 cell medium, supplemented with human epidermal growth factor (EGF; 10 ng·mL À1 ), N2 supplement (1% v.v -1 ) and human basic fibroblast growth factor (bFGF, 10 ng·mL À1 ).
The medium was freshly prepared and added every other day. On day 14, the cells were inspected under a microscope for sphere formation.
Cell viability assay
LCSCs and dLCSCs were seeded in 96-well plates at a density of 4000 cells per well. They were treated with cisplatin at 0, 12.5, 25, 50, 75 and 100 μM for 8 and 12 h. Cells without cisplatin treatment were used as the untreated control. For treated cells, the cisplatin-containing media were then removed and replaced with fresh complete DMEM with 10% FBS and antibiotics. After further incubation, at the endpoint of 48 h, cell viability after each treatment was assessed by an MTT assay. Briefly, 10 μL of MTT solution in PBS (5 mg·mL À1 ) was added to each well, and the sample plate was incubated at 37°C for 4 h. A total of 100 μL of pure DMSO was added to each well to dissolve the purple formazan crystals. Absorption measurement at 560 nm was subsequently carried out using a 96-well plate reader.
Whole cell platinum accumulation assay
A hundred thousand each of LCSCs and dLCSCs were seeded and cultured in 55 cm 2 culture dishes, allowed to grow to 90% confluence and treated with 50 μM cisplatin for 4 h. Cells were subsequently harvested and washed with PBS three times. Cell numbers were counted using haemocytometer, and the entire cell pellets were digested by 65% nitric acid at 65°C overnight. Pt content in the digestion solutions wasdetermined by an inductively-coupled plasma-mass spectrometer, (ICP-MS, Perkin Elmer, Elan 6100 DRC), which was subsequently divided by the total cell count (10 6 ) of the pellet to calculate Pt content per cell.
Immunoslot blot assay
LCSCs and dLCSCs were treated with 50 μM cisplatin for 4 and 12 h. Cells were then harvested, and genomic DNA was extracted using a mammalian genomic DNA miniprep kit (Sigma). After quantification of DNA by a spectrophotometer (Nanodrop, ND-1000, ThermoFisher), 5 μg of denatured DNA from the control (without cisplatin treatment) and treatment groups was slot-blotted to nylon membranes (Amersham Hybond-N+, GE healthcare) and fixed by heating at 80°C for 2 h. Cisplatin-induced DNA intrastrand cross-links (Pt-GG) were detected by an anti-Pt-GG primary antibody (oncolyze, German) followed by HRP-conjugated goat anti-rat IgG secondary antibody (Life Technologies). The chemiluminescence was recorded on Fujifilm Gel Doc LAS-4000. The intensity of each band was quantified by use of Multi Gauge V3.2 software.
Comet assay
The extent of cisplatin-DNA ICLs was assessed by an alkaline comet assay with some modifications according to the literature (Arora et al., 2010) . Each type of cell was treated with 25 or 50 μM cisplatin for 12 h in complete media, washed with PBS and incubated in cisplatin-free fresh medium for another 0 (t = 0) or 12 (t = 12) h. Afterwards, cells were further treated with 100 μM hydrogen peroxide for 15 min to induce DNA strand breaks. Comet assays were then carried out using the OxiSelect 96-Well comet assay kit (Cell Biolabs, San Diego, CA) according to the manufacturer's instructions. The resulting comets were analysed using a Leica SPE confocal microscope at 200× magnification. Fifty cells per slide were randomly picked and analysed using the Comet Assay IV software. The level of ICLs was calculated by use of the following formula:
, where TM pt is the mean tail moment of the cisplatin + H 2 O 2 -treated sample, TM ctl is the mean tail moment of the untreated control sample and TM H2O2 is the mean tail moment of H 2 O 2 treated sample. The data are expressed as a percentage of ICLs that remained at a particular time point where the % at 0 h was normalized to 100%. The tail moment was defined as the products of tail length (the mean distance of migration in the tail) and amount of DNA in the tail region (tail DNA intensity) (Olive et al., 1990) .
Transcription-coupled DNA repair assay
Plasmid construction, preparation and transient transfection into the human lung cancer cells were carried out as previously described (Zhu et al., 2012) . Briefly, a mammalian plasmid expressing Gaussia luciferase without the SV40 origin of replication, pGLuc (3983 BP), was constructed. Globally platinated plasmids were prepared accordingly, and Pt contents were determined by ICP-MS (PerkinElmer, USA). DNA concentrations were measured by absorption measurement at 260 nm on the Nanodrop. The levels of Pt were 15.26 and 30.05 Pt per plasmid. LCSCs and dLCSCs were plated at 5000 cells per well in 96-well plates and allowed to attach and grow for 48 h. Cells were then washed with antibiotic-free culture media just before transfection. The experiments were performed in quadruplicate. The plasmids were diluted in OptiMEM (Invitrogen), and Lipofectamine was diluted separately in OptiMEM. After 5 min incubation at room temperature, the two solutions were then mixed and incubated for 20 min at room temperature. The transfection mixture was delivered into each well, and the cells were incubated for 2 h at 37°C. After transfection, cells were washed with PBS and added to antibiotic-free DMEM/F-12 medium with 10% FBS. Media after various incubation times were collected for subsequent luminescence analysis, and fresh antibiotic-free media were added after each collection. The collected media were stored at 4°C in the dark before luminescent measurement of Gaussia luciferase. The inhibitory effect of cisplatin on the transcription of LCSCs and dLCSC was determined by quantification of expressed luciferase using coelenterazine as a substrate.
Group size, randomization and blinding
Each sample was tested in triplicate for each experiment, and five repeat experiments (n = 5) were performed with different samples under the same treatment for each assay. The number of experiments is also stated on the figure legends under each figure. For the comet assay, the data from 50 cell comets for each sample were randomly selected by another researcher who did not participate in the earlier experiment. The method used to measure tail moments was computed by the Comet Assay IV software to exclude human judgement bias. For immunostaining, 10 000 live cell events were randomly collected and analysed by the BD FACSDiva ™ software.
Data and statistical analysis
The data and statistical analysis comply with the recommendations on experimental design and analysis in pharmacology (Curtis et al., 2015) . All values are expressed as mean AE SEM. Statistical analysis was carried out using one-way ANOVA followed by an appropriate post hoc test only when the F value from ANOVA reached statistical significance (F < 0.05). As there was no significant variance inhomogeneity in groups of data, ANOVA was carried out using GraphPad PRISM version 5.01 (La Jolla, CA, USA, www.graphpad.com). Technologies) . Globally platinated plasmids were prepared as previously described (Zhu et al., 2012) . All other reagents and chemicals were from standard suppliers.
Results
LCSCs have distinct cluster morphology and high stemness properties
We first examined the morphological properties of LCSCs and dLCSCs. The dLCSCs originated from LCSCs after 12 passages (P13) in the culture. Figure 1A shows the distinct cell morphologies between LCSCs and dLCSCs. LCSCs grew in clusters, but the cluster morphology had disappeared in dLCSCs. LCSCs had a higher proliferation rate in log phase than dLCSCs ( Figure 1B) , and tumour sphere formation was observed for LCSCs but not dLCSCs ( Figure 1C) . Moreover, immunostaining results showed higher Oct4 expression levels in LCSCs after staining with FITC-conjugated Oct4 antibody, with 76.7% Oct4-positive LCSCs and 0.9% Oct4-positive dLCSCs. A strong fluorescent signal for Oct4-FITC was also observed in fluorescence images of LCSCs ( Figure 1D ). The stemness of these cells was further characterized by the expression level of a number of stemness-related genes. Significantly enhanced levels of expression of stemness-related genes, such as Notch 1, c-Myc, Klf-4, Sox2 and Oct4, were found in LCSCs ( Figure 1E ) when compared with dLCSCs. These results demonstrate the differences between LCSCs and dLCSCs and indicate that LCSCs have enhanced stemness properties and tumourigenicity.
LCSCs are resistant to the effects of cisplatin treatment
The cytotoxicity of cisplatin on LCSCs and dLCSCs was determined first. Cells were treated with different concentrations of cisplatin for 8 and 12 h, and were further incubated in the fresh media until the endpoint of 48 h. Cell viability was determined by the MTT assay. As shown in Figure 2A -B, LCSCs had significantly higher viability than dLCSCs at both time points. For example, after a 12 h
Figure 1 treatment with 25 μM cisplatin, the viability of LCSCs at 48 h was 92.5%, but those of dLCSCs was only 56.8%. Cisplatin displayed higher IC 50 values in LCSCs than in dLCSCs under different treatment conditions ( Figure 2C ). For instance, the corresponding IC 50 values of cisplatin in LCSCs and dLCSCs were 57.1 and 37.5 μM, respectively, after a 12 h drug treatment.
LCSCs have reduced cisplatin accumulation at both the cellular and genomic DNA levels Different mechanisms including reduced cellular uptake and elevated DNA repair contribute to the reduced cytotoxicity of cisplatin in lung cancer cells (Xia and Hui, 2014) .
We examined the accumulation of cisplatin in LCSCs and dLCSCs. The cells were treated with 50 μM cisplatin for 4 h, and the cellular level of platinum was assessed by inductively coupled plasma-mass spectrometry (ICP-MS). The levels of platinum in LCSCs and dLCSCs were 83.69 and 144.83 ng Pt per 10 6 cells respectively ( Figure 3A ). Therefore, compared with dLCSCs, LCSCs showed a significantly lower level of platinum inside the cells. We next performed an immunoslot blot assay to determine the platinum levels in genomic DNA (Kang and Leem, 2014) . Cells were treated with 50 μM cisplatin for 4 or 12 h, and a fixed amount of DNA was blotted onto the nylon membrane. The level of platinum-d(GpG) cross-links, the major adducts formed by cisplatin (Wang and Lippard, 2005) , was visualized by using an anti-Pt-GG primary antibody followed by an HRPconjugated goat anti-rat IgG secondary antibody. Apparently, higher levels of cisplatin-DNA intrastrand cross-links were detected in dLCSCs compared with those in LCSCs ( Figure 3B ). For example, after a 4 h treatment, the relative band intensities in LCSCs and dLCSCs were 4.04 and 8.94 respectively. Taken together, cisplatin accumulates in LCSCs less efficiently than in dLCSCs, resulting in reduced levels of platinum cross-linking on genomic DNA, which may be one of the reasons for cisplatin's decreased cytotoxicity in LCSCs. In order to explain the lower cisplatin accumulation in LCSCs, real-time PCR of various transporter genes was performed for the two cell lines without cisplatin incubation. Figure 3C shows the reduced expression of AQP2, ATP7B and CTR1 influx transporters in LCSCs (fold change: 0.60, 0.44 and 0.55, respectively), while other genes, such as AQP9 and CTR2, did not exhibit any significant difference. The low Transcription-coupled repair of Pt-DNA cross-links Another possible reason for the different cytotoxicity in LCSCs and dLCSCs may result from their different DNA repair capability. We, therefore, carried out a transcription-coupled DNA repair assay using globally platinated plasmids (Ang et al., 2010) . The plasmid encodes secreted Gaussia luciferase that is quantified by a luciferase assay. The presence of Pt-DNA cross-links in the plasmids results in transcription inhibition, and the repair of the DNA damage leads to the recovery of transcription activity ( Figure 4A ). This assay has been used to determine the transcription-coupled repair mechanism of different types of Pt-DNA lesions in a variety of mammalian cancer cell lines (Zhu et al., 2012; Zhu et al., 2013) . In this study, the cells were transfected with globally platinated plasmids containing 15.26 and 30.05 Pt per plasmid, and the transcription levels were determined at 8, 16, 24, 32 and 44 h. Unmodified plasmid was used as a control, and its expression level was normalized to 100%. In LCSCs, the transcription level recovered from 19.5% at 8 h to 72.9% at 44 h for 15.26 Pt per DNA, while in dLCSCs, the levels were 4.6 and 22.3% at 8 and 44 h, respectively, showing the marked increased repair of Pt-DNA cross-links in LCSCs ( Figure 4B ). Identical effects were observed at 30.05 Pt per DNA ( Figure 4C ). In addition, D 50 values, the number of Pt adducts per plasmid required to reduce the transcription levels to 50% of the control (Wang et al., 2014a) , were obtained to quantify the differences in transcription inhibition among the two cell lines. Increased D 50 values over time indicated an increased ability of the DNA damage repair on the plasmid. For LCSCs, D 50 values increased significantly at different time points, showing the higher DNA repair capability of LCSCs compared to that of dLCSCs ( Figure 4D ). These data indicate that LCSCs have a higher DNA repair capability than dLCSCs to remove Pt-DNA damage.
Repair of cisplatin interstrand cross-links (ICLs)
We also used the Comet assay to measure the level of cisplatin-DNA ICLs at the single cell level in the two cell lines (Arora et al., 2010) . Cells were treated with 25 or 50 μM cisplatin for 12 h and subsequently incubated in cisplatin-free media for 12 h. The repair of ICLs was monitored within this period of time. Representative images of gel electrophoresis are shown in Figure 5A , and the remaining images are included in Figure S1 of supporting information. Tables summarizing the tail moments, ICLs and normalized values are Table S2 -4 for further elucidating the data. The repair of cisplatin ICLs was evaluated over 12 h after treatment and expressed as the percentage of ICLs remaining at 12 h ( Figure 5B ). The lower percentage of ICLs remaining indicates a higher degree of repair. LCSCs showed a greater reduction in ICL levels than dLCSCs. For example, after 25 μM cisplatin treatment, the levels of ICLs in LCSCs and dLCSCs were 55.6 and 95.4%, respectively, indicating a higher level of ICL repair in LCSCs. These results show that LCSCs were able to remove Pt-DNA ICLs in genomic DNA much more efficiently, further proving that LCSCs have a higher DNA repair capability than dLCSCs.
Up-regulation of DNA repair-related genes in LCSCs
To further investigate the molecular mechanism of the enhanced DNA repair capability in LCSCs, the expression of DNA repair genes was analysed by real-time PCR. The two cell lines were incubated with 50 μM cisplatin for 12 h. In the control group, cells were cultured in cisplatin-free medium for the same amount of time. After treatment, the fold change in DNA repair-related genes was analysed. It was found that several genes were significantly up-regulated in LCSCs when compared with dLCSCs. For example, the fold changes in ERCC1, MLH1 and MSH2 in LCSCs were 3.62, 2.56 and 3.97, respectively, while they were 1.74, 1.80 and 2.86 in dLCSCs (P < 0.05). LCSCs also showed higher expression of PMS2 and RAD51 than dLCSCs, but the differences were not significant (LCSCs and dLCSCs =2.44 and 1.87 for PMS2; 2.15 and 2.03 for RAD51). RAD51 and ERCC1 are related to the DSB and NER pathways, respectively (Olaussen et al., 2006; Hashimoto et al., 2012) , while MLH1, MSH2 and PMS2 take part in the MMR pathway (Prolla et al., 1994; Kondo et al., 2001) . The results show that NER and MMR pathways may play an important role in the enhanced DNA repair capability in LCSCs.
Discussions and conclusion
LCSCs expressed high levels of stemness-related genes, such as Notch1, c-Myc, Klf-4, Sox2 and Oct4. These genes have been commonly investigated in cancer stem cell studies (Shi and Ai, 2013) . The high stemness properties have also been correlated with the ability to form tumour spheres (Eramo et al., 2008) . When LCSCs differentiated into dLCSCs, the cell cluster morphology of the LCSCs changed to fibroblast-like and was associated with a loss of stemness and the ability to form tumour spheres. These results indicate that the LCSCs used in this study possessed both stemness properties and tumourigenicity.
Cancer cells may become resistant to DNA-damaging chemotherapeutics by changing the drug influx or efflux rates, deactivating the drug target by mutation or altering the DNA repair capability (Xia and Hui, 2014) . Recently, cisplatin resistance has been correlated with the stem-like characteristics of lung cancer cells (Barr et al., 2013) . Cisplatin-resistant cells have been found to have an increased ability to repair DNA (Olaussen et al., 2006) , which increases the survival of cancer cells. Although the NER pathway was implicated in the removal of cisplatin-DNA intrastrand cross-links in lung cancer cells (Graf et al., 2011; Enoiu et al., 2012) , the repair pathways that are responsible for the processing of Pt-DNA cross-links in LCSCs and the DNA repair capability of LCSCs have not been studied in detail.
We first demonstrated that one mechanism for cisplatin resistance in LCSCs is due to a reduction in the accumulation of cisplatin in the whole cell, which could arise from reduced cisplatin uptake or elevated cisplatin efflux in LCSCs. The immunoslot blot assay showed that the degree of platinum damage in genomic DNA was lower in LDSCs; this may result from both the reduced cellular accumulation of cisplatin and the enhanced ability of these cells to repair DNA damage. The expression of various transporters was also investigated in the present study to determine whether the lower cellular accumulation of cisplatin was due to differences in its influx or efflux. AQP2 and AQP9 are aquaporin transporters, which are mainly responsible for the passage of water molecules (van Lieburg et al., 1995; Ishibashi et al., 1998) . Although a connection between aquaporins and cisplatin transport is not clear, reduced AQP2 and AQP9 expression has been correlated with increased cisplatin resistance (Hall et al., 2008; Wang et al., 2014b) . Our real-time PCR results revealed a down-regulation of AQP2, which may lead to a reduced cellular platinum level thus elevating cisplatin resistance; but there was no significant change in AQP9. The copper efflux transporters, ATP7A and ATP7B, have also been reported to have a role in cisplatin efflux; therefore, increase expression of these transporters could reduce the level of intracellular cisplatin and induce resistance to platinum drugs (Komatsu et al., 2000; Katano et al., 2002) . However, we found that the expression ATP7 and ATP7B was either insignificant or even downregulated. Hence, they are unlikely to contribute to the reduced platinum level in the cell.
The other copper transporters, CTR1 and CTR2, also regulate cellular copper levels by controlling the cellular intake or efflux of copper (Luk et al., 2003) . Studies have shown that CTR1 is responsible for controlling cisplatin uptake and regulating sensitivity to platinum drugs (Ishida et al., 2002; Safaei and Howell, 2005; Larson et al., 2009) , while recent evidence demonstrated that a down-regulation of CTR2 increased cisplatin accumulation (Blair et al., 2010) . Our results showed that while CTR2 did not exhibit any significant difference between the two cell lines, the lower expression of CTR1 in LCSCs may contribute to the reduced intracellular accumulation of cisplatin in LCSCs. The downregulation of AQP2 and CTR1 may work together to cause a lower platinum level in LCSCs, conferring increased resistance.
The enhanced DNA repair capability in LCSCs was subsequently validated by the transcription inhibition profiles of the two cell lines. The lower recovery of transcription in dLCSCs from 8 to 44 h was attributed to a reduced ability to repair the cisplatin-damaged plasmid. LCSCs had a much higher transcription recovery than dLCSCs, suggesting the efficient removal of any remaining Pt-DNA crosslinks and extensive activation of DNA repair genes. The removal of cisplatin ICLs in the genomic DNA of LCSCs was confirmed by the Comet assay. All these results provide solid evidence that the LCSCs are more resistant to cisplatin than dLCSCs because of both a reduction in the cellular accumulation of this drug and an enhanced DNA repair capability.
The molecular mechanisms involved in the DNA repair capability of LCSCs were evaluated based on the expression profiles of various DNA repair genes. The results demonstrated that the NER and MMR pathways were activated in LCSCs by the cisplatin treatment. In the NER pathway, the up-regulation of endonucleases such as ERCC1 has a major role in cisplatin-induced DNA damage repair (Arora et al., 2010) . Overexpression of ERCC1 is known to correlate with resistance to platinum-based chemotherapy (Olaussen et al., 2006; Steffensen et al., 2009) .
Although the expression change of RAD51 in LCSCs and dLCSCs upon cisplatin treatment was not significantly different (P > 0.05), both cell lines showed an increase in RAD51 expression. This result implies the possible activation of the DSB pathway in both cell lines. Within this pathway, it was reported that MRE11 would interact with RAD51 monomers to form the replisome to facilitate the removal of DNA damage (Hashimoto et al., 2012) . The expression of the RAD51 paralog is associated with the overexpression of XRCC3, which also has a role in DNA damage repair (Xu et al., 2005) .
Mismatch repair (MMR) is another important pathway in DNA damage repair. Studies have revealed that MLH1, MSH2 and PMS2 are important components in MMR, and they form the heterodimers complex for the recognition of the mismatched damage (Prolla et al., 1994; Wang et al., 1999; Kondo et al., 2001) . We observed greater fold change of MLH1, MSH2 and PMS2 in LCSCs after cisplatin treatment than in dLCSCs, which suggests that an increase in the activity of the MMR pathway in LCSCs may improve cisplatin-induced repair. Although it remains unclear how the MMR pathway was activated in the cisplatin-treated LCSCs to induce repair, it is known that ERCC1, which is the mammalian homologue of Rad10, is able to interact with MSH2 (Schrader et al., 2004) . When ERCC1 and MSH2 are both highly expressed in LCSCs, the DNA repair might be enhanced. Overall, the results from this study show that while the DSB pathway was activated in both cell lines, the NER and MMR pathways were more strongly activated in LCSCs, which may account for its higher repair capabilities.
In conclusion, we have carried out a detailed study on the mechanism of cisplatin resistance in LCSCs and their differentiated counterpart dLCSCs. LCSCs were found to be more resistant to the cytotoxic effects of cisplatin treatment than dLCSCs. The cellular accumulation of cisplatin and the level of platinum on genomic DNA were lower in LCSCs than in dLCSCs, possibly due to a down-regulation of the influx transporters AQP2 and CTR1, leading to an elevated cisplatin resistance in LCSCs. The greater DNA repair capability of LCSCs compared to dLCSCs was further validated by the transcription-coupled repair assay and the Comet assay, and is likely to be the result of the activation of DNA repair pathways such as NER, DSB and MMR. This study provides insights into the mechanism of cisplatin resistance in LCSCs and sheds light on the design of the next-generation of anticancer agents that may be a more effective treatment against LCSCs. Platinum agents that are able to accumulate in LCSCs, and can form Pt-DNA adducts in these cells that are difficult to remove will be promising anticancer drug candidates.
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